Trial Profile
A multi-dosing study of AB-423 in HBV patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2017
Price :
$35
*
At a glance
- Drugs AB 423 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 02 Nov 2017 According to an Arbutus Biopharma Corporation media release, this trial is expected to be initiated in the first quarter of 2018.
- 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, this trial is expected to initiate by the end of 2017.
- 10 May 2017 New trial record